Indacaterol Dosage

Usual Adult Dose for Chronic Obstructive Pulmonary Disease - Maintenance

1 inhalation (75 mcg) orally once a day

Comment:

• This drug should not be used more than one time every 24 hours.

Use: Long term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema

Renal Dose Adjustments

No adjustment is recommended

Liver Dose Adjustments

Mild to moderate liver dysfunction: No adjustment recommended
Severe liver dysfunction: No data available

Precautions

CONTRAINDICATIONS:

• Hypersensitivity to any of the ingredients
• Use of a long-acting beta-2 (LABA) agonist without an inhaled corticosteroid (ICS) in asthma patients; this drug is not indicated for asthma treatment

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• For oral inhalation only.
• Capsules should not be swallowed, it should only be used with the NEOHALER device.
• Administer this drug at the same time of the day.
• The recommended daily dose should not be exceeded.
• Missed dose: The next dose should be taken as soon as it is remembered.
• To ensure proper use of the inhaler device, consult the manufacturer product information.

Storage requirements:

• Capsules should be stored in the blister, and only removed immediately before use with the inhaler device.

Limitations of use:

• This drug is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease or to treat asthma.
• The safety and effectiveness of this drug in patients with asthma have not been established.

Patient advice:

• Patients should read the medication guide and instructions for the use of this drug.
• A rescue inhaler should be provided to patients to treat acute symptoms. Patients should be instructed on how to use the rescue inhaler.
• Notify the physician immediately if experiencing any of the following: Worsening of symptoms; decreasing effectiveness of inhaled, short-acting beta2-agonists; need for more inhalations than usual of the inhaled, short-acting beta2-agonists; significant decrease in lung function.
• Therapy with this drug should not be stopped without physician/provider guidance since symptoms may recur after discontinuation.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer